Market News / Story
Genentech Wins FDA OK for Tecentriq Combo in Stage III dMMR Colon Cancer
·
The FDA approved Tecentriq and Tecentriq Hybreza with a fluoropyrimidine and oxaliplatin for adjuvant treatment of Stage III dMMR colon cancer, based on Phase III ATOMIC data showing a 50% reduction in risk of recurrence or death vs chemo alone. Material Details #DetailAI Analyst View1FDA approves Tecentriq combo in adjuvant CRCRegulatory greenlight expands label into Stage III dMMR colon cancer, opening a new reimbursable use.2ATOMIC cut DFS risk by 50% vs chemoStrong…